@article {FUJITA3917, author = {KOHEI FUJITA and NAOHIRO UCHIDA and YUKI YAMAMOTO and OSAMU KANAI and MISATO OKAMURA and KOICHI NAKATANI and SATORU SAWAI and TADASHI MIO}, title = {Retreatment With Anti-PD-L1 Antibody in Advanced Non-small Cell Lung Cancer Previously Treated With Anti-PD-1 Antibodies}, volume = {39}, number = {7}, pages = {3917--3921}, year = {2019}, doi = {10.21873/anticanres.13543}, publisher = {International Institute of Anticancer Research}, abstract = {Aim: To evaluate the efficacy and safety of re-treatment with anti-programmed death (PD)-L1 antibody (atezolizumab) after anti-PD-1 antibody (nivolumab/pembrolizumab) treatment in advanced non-small cell lung cancer (NSCLC) patients. Patients and Methods: We retrospectively reviewed 18 NSCLC patients who received atezolizumab after anti-PD-1 antibody treatment. Data on patient characteristics, number of cycles of anti-PD-1 antibody and atezolizumab, regimens between anti-PD-1 antibody and atezolizumab, best response, and immune-related adverse events (irAEs) were collected and analyzed. Results: Nine patients a had high (>=50\%) PD-L1 expression. The median number of cycles of atezolizumab was 3 (range=2-7). The median progression-free survival was 2.9{\textpm}1.8 months. Seven (38.9\%) and 11 (61.1\%) patients had stable and progressive disease, respectively. No patient achieved partial or complete response. There were no significant differences in the occurrence of irAEs between anti-PD-1 antibodies and atezolizumab. Conclusion: Preliminary results showed that patients previously treated with anti PD-1 antibodies received only limited benefit from subsequent atezolizumab.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/39/7/3917}, eprint = {https://ar.iiarjournals.org/content/39/7/3917.full.pdf}, journal = {Anticancer Research} }